Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
598.00    -6.00 (-0.99%)
Bid:
596.00
Ask:
598.00
Spread: 2.00 (0.336%)
Market Cap: £521.00m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

US FDA approval: Total Knee Study

17 Sep 2024 14:00

RNS Number : 5569E
Victrex PLC
17 September 2024
 

17 September 2024

Victrex plc

US FDA Approval for Total Knee Arthroplasty Study in the US

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and enable environmental and societal benefit in multiple end-markets.

The Group today announces that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom® Total Knee System with Invibio PEEK-OPTIMA™ Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA™ Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components.

 

The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.

 

Jakob Sigurdsson, Chief Executive of Victrex, said: "PEEK Knee has the potential to be a game-changer for total knee replacement. Being able to further assess its benefits through rigorous clinical evaluation in the US will build on the strong progress so far through clinical trial sites in Europe and India. We look forward to the study's progression and remain optimistic about the transformative impact this pioneering device could have on the future of joint replacement.

 

"In relation to the regulatory submission in India, following a tenacious focus on innovation, development and investment to scale this significant opportunity, we now look forward to the potential for a PEEK Knee being in the market during 2025 and commercial revenues. We also continue to see growing interest in PEEK Knee from across the medical device industry, beyond our existing collaborations."

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVFARIDLIS
Date   Source Headline
10th May 20231:34 pmRNSDirector/PDMR Shareholding
9th May 20237:00 amRNSVictrex plc - Interim Results 2023
28th Apr 20239:33 amRNSTotal Voting Rights
18th Apr 20232:00 pmRNSHolding(s) in Company
18th Apr 202310:50 amRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSDirectorate Change
31st Mar 202310:52 amRNSTotal Voting Rights
20th Mar 20233:07 pmRNSHolding(s) in Company
20th Mar 202310:15 amRNSDirector/PDMR Shareholding
13th Mar 202310:14 amRNSAdditional Listing
28th Feb 20239:35 amRNSTotal Voting Rights
17th Feb 202310:06 amRNSDirector/PDMR Shareholding
14th Feb 202312:20 pmRNSDirector/PDMR Shareholding
10th Feb 20232:12 pmRNSDirector/PDMR Shareholding
10th Feb 202312:29 pmRNSResult of AGM
10th Feb 20237:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202310:43 amRNSTotal Voting Rights
17th Jan 20232:12 pmRNSDirector/PDMR Shareholding
12th Jan 20232:28 pmRNSCorrection - AGM Resolution Proposal
6th Jan 20232:58 pmRNSAnnual Report and Accounts
30th Dec 20229:00 amRNSTotal Voting Rights
22nd Dec 202211:30 amRNSDirector/PDMR Shareholding
19th Dec 202212:04 pmRNSDirector/PDMR Shareholding
19th Dec 202210:56 amRNSDirector/PDMR Shareholding
13th Dec 202211:16 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSVictrex plc – Preliminary Results 2022
1st Dec 202211:49 amRNSBlock listing Interim Review
30th Nov 20229:27 amRNSTotal Voting Rights
29th Nov 20224:05 pmRNSHolding(s) in Company
17th Nov 20222:50 pmRNSDirector/PDMR Shareholding
17th Nov 20221:35 pmRNSAdditional Listing
31st Oct 202212:55 pmRNSTotal Voting Rights
18th Oct 202212:26 pmRNSDirector/PDMR Shareholding
30th Sep 202211:03 amRNSTotal Voting Rights
28th Sep 20229:44 amRNSHolding(s) in Company
20th Sep 20224:05 pmRNSDirector/PDMR Shareholding
31st Aug 20229:00 amRNSTotal Voting Rights
17th Aug 20222:31 pmRNSDirector/PDMR Shareholding
29th Jul 202210:01 amRNSTotal Voting Rights
19th Jul 20222:41 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202210:28 amRNSTotal Voting Rights
21st Jun 202212:41 pmRNSDirector/PDMR Shareholding
7th Jun 202211:45 amRNSBlock listing Interim Review
31st May 20229:59 amRNSTotal Voting Rights
27th May 20229:40 amRNSHolding(s) in Company
17th May 20223:58 pmRNSHolding(s) in Company
17th May 202212:19 pmRNSDirector/PDMR Shareholding
13th May 202211:02 amRNSDirector/PDMR Shareholding
9th May 20227:00 amRNSVictrex plc – Interim Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.